All mpox articles
-
NewsStudy yields new data on Mpox vaccine effectiveness in people with HIV
A new study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer sufficient protection. All at-risk groups, especially people with HIV, should receive the second dose of the vaccine as recommended.
-
NewsTecovirimat is safe but ineffective as treatment for clade II mpox
The antiviral drug tecovrimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial.
-
NewsNew insights offer hope for developing antiviral therapeutics targeting mpox
New research provides novel perspectives on the biological function of G4s in the lifecycle of MPXV and offer potential avenues for developing antiviral therapeutics targeting mpox prevention and treatment.
-
NewsOptical biosensor rapidly detects monkeypox virus
Researchers have developed an optical biosensor that can rapidly detect monkeypox, the virus that causes mpox. The technology could allow clinicians to diagnose the disease at the point of care rather than wait for lab results.
-
NewsPotential single-dose smallpox and mpox vaccine moves forward
Scientists report on studies suggesting that the horsepox virus in the experimental vaccine is substantially more attenuated—and less likely to trigger a systemic infection—than the vaccinia virus used in the single-dose vaccine already approved by the FDA.
-
NewsVaccinating children for mpox would significantly reduce deaths in the DRC
Vaccinating children under five-years-old in endemic mpox regions in the Democratic Republic of the Congo (DRC) would significantly reduce the number of deaths in the country, according to a new analysis.
-
NewsMpox vaccine is safe and generates a robust antibody response in adolescents
A clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to a planned interim analysis of study data.
-
NewsNovel app tracks travel-related illnesses
Travelers fall ill surprisingly often during their travels, with health issues occurring on more than one-third of trips, reveals data collected by a novel travel app developed by researchers in cooperation with the World Health Organization (WHO).
-
NewsNew risks raise pandemic threat on a global scale: GPMB warning
A plethora of risks increase the likelihood of new pandemics according to a new report from the Global Preparedness Monitoring Board (GPMB).
-
NewsViral messaging can deliver lessons on how infectious diseases spread
A new study explores a hybrid approach to understanding social networks that involves inferring not just social contacts but also the rules that govern how contagion and information spread.
-
NewsThe Democratic Republic of the Congo kicks off mpox vaccination
The Democratic Republic of the Congo today kicked off mpox vaccination, adding a vital measure to complement the ongoing outbreak control efforts to halt the spread of the viral disease and save lives. Source: NIAID Colorized transmission electron micrograph of mpox virus particles (teal) cultivated and purified ...
-
NewsNIH releases mpox research agenda
National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) has released an update on its priorities for mpox research, which focus on four key objectives.
-
NewsOne dose of smallpox vaccine moderately effective in preventing mpox infection
One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) smallpox vaccine is moderately effective in preventing mpox infection and should be made available to communities at risk, finds a new study.
-
NewsInvestigational mpox mRNA vaccine reduces disease severity in primates compared to available vaccines
A new mpox vaccine candidate more effectively limits symptoms and disease duration in primates that were infected with a lethal strain of the mpox virus when compared to a currently licensed modified vaccinia Ankara (MVA) vaccine.
-
NewsWHO declares mpox outbreak a public health emergency of international concern
WHO Director-General Dr Tedros Adhanom Ghebreyesus has declared that the upsurge of mpox in the Democratic Republic of the Congo and a growing number of countries in Africa constitutes a public health emergency of international concern.
-
NewsWHO convenes Emergency Committee to tackle mpox surge in Congo and neighbours
WHO Director-General Tedros Adhanom Ghebreyesus announced the convening of an Emergency Committee under International Health Regulations to advise on whether the Africa outbreak represents a public health emergency of international concern.
-
NewsSyphilis cases are rising, but many people don’t know the symptoms
Syphilis cases are on the rise around the globe, but many Americans don’t know the symptoms. Just over half know that a case of syphilis can be permanently cured and most either mistakenly think there is a vaccine to prevent it or are unsure.
-
NewsMpox circulating at low numbers among gay and bisexual men who have sex with men
While mpox cases have sharply declined since the 2022 global outbreak, they continue to occur in the U.S. among gay and bisexual men who have sex with men (GBMSM), according to a new study.
-
NewsScientists uncover factors potentially contributing to the decline of the mpox outbreak
Researchers hypothesise that it is not likely that preventive vaccination was a driver of the outbreak’s decline in the Netherlands, as the mpox incidence started to decline before the start of the vaccination programme.
-
NewsLower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen
A dose-sparing intradermal mpox vaccination regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks (two weeks after the second dose), according to new findings.